Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVR NASDAQ:BBNX NASDAQ:DCTH NASDAQ:NPCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$4.02-2.0%$3.57$2.34▼$8.79$144.96MN/A200,128 shs55,212 shsBBNXBeta Bionics$19.88+1.0%$15.39$8.89▼$24.50$864.18MN/A524,480 shs152,565 shsDCTHDelcath Systems$11.01+1.0%$11.35$8.08▼$18.23$385.84M0.85574,055 shs189,463 shsNPCENeuroPace$9.60+2.5%$9.31$5.45▼$18.98$317.20M1.9270,534 shs145,278 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global-0.24%+12.02%+19.53%-17.34%+409,999,900.00%BBNXBeta Bionics+3.47%+3.74%+19.85%+0.66%+1,967,999,900.00%DCTHDelcath Systems0.00%-0.37%-3.28%-35.39%+3.22%NPCENeuroPace+2.41%+5.41%+4.82%-29.52%+26.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$4.02-2.0%$3.57$2.34▼$8.79$144.96MN/A200,128 shs55,212 shsBBNXBeta Bionics$19.88+1.0%$15.39$8.89▼$24.50$864.18MN/A524,480 shs152,565 shsDCTHDelcath Systems$11.01+1.0%$11.35$8.08▼$18.23$385.84M0.85574,055 shs189,463 shsNPCENeuroPace$9.60+2.5%$9.31$5.45▼$18.98$317.20M1.9270,534 shs145,278 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global-0.24%+12.02%+19.53%-17.34%+409,999,900.00%BBNXBeta Bionics+3.47%+3.74%+19.85%+0.66%+1,967,999,900.00%DCTHDelcath Systems0.00%-0.37%-3.28%-35.39%+3.22%NPCENeuroPace+2.41%+5.41%+4.82%-29.52%+26.66%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$2.70M53.69N/AN/A$0.67 per share6.00BBNXBeta Bionics$78.02M11.08N/AN/A$6.94 per share2.86DCTHDelcath Systems$70.24M5.48N/AN/A$3.00 per share3.67NPCENeuroPace$79.91M3.97N/AN/A$0.59 per share16.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies Global-$76.29MN/A0.00N/AN/AN/AN/AN/A11/10/2025 (Estimated)BBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/ADCTHDelcath Systems-$26.39M$0.05220.60N/AN/A3.18%6.91%5.80%11/14/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.29%-168.61%-25.48%11/11/2025 (Estimated)Latest AVR, BBNX, NPCE, and DCTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025NPCENeuroPace-$0.24-$0.26-$0.02-$0.26$23.08 million$23.52 million8/11/2025Q2 2025 TUAVRAnteris Technologies Global-$0.5333-$0.58-$0.0467-$0.58$0.58 million$0.62 million8/6/2025Q2 2025DCTHDelcath Systems$0.02$0.07+$0.05$0.07$22.84 million$24.16 million7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies GlobalN/A2.412.38BBNXBeta BionicsN/A14.6813.79DCTHDelcath SystemsN/A10.889.87NPCENeuroPace3.025.474.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ABBNXBeta BionicsN/ADCTHDelcath Systems61.12%NPCENeuroPace78.83%Insider OwnershipCompanyInsider OwnershipAVRAnteris Technologies Global4.00%BBNXBeta BionicsN/ADCTHDelcath Systems17.40%NPCENeuroPace20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13836.06 million34.62 millionN/ABBNXBeta Bionics29443.47 millionN/AN/ADCTHDelcath Systems6034.98 million28.71 millionOptionableNPCENeuroPace17033.08 million26.30 millionOptionableAVR, BBNX, NPCE, and DCTH HeadlinesRecent News About These CompaniesFirst Light Asset Management LLC Takes Position in NeuroPace, Inc. $NPCESeptember 4 at 7:27 AM | marketbeat.comNantahala Capital Management LLC Lowers Stake in NeuroPace, Inc. $NPCESeptember 3 at 7:08 AM | marketbeat.comGhisallo Capital Management LLC Buys Shares of 200,000 NeuroPace, Inc. $NPCESeptember 2 at 8:33 AM | marketbeat.comArmistice Capital LLC Purchases 561,000 Shares of NeuroPace, Inc. $NPCESeptember 2 at 8:12 AM | marketbeat.comDriehaus Capital Management LLC Purchases Shares of 803,440 NeuroPace, Inc. $NPCESeptember 2 at 5:57 AM | marketbeat.comRussell Investments Group Ltd. Takes $552,000 Position in NeuroPace, Inc. $NPCESeptember 2 at 3:52 AM | marketbeat.comWalleye Capital LLC Boosts Stock Position in NeuroPace, Inc. $NPCESeptember 1 at 4:24 AM | marketbeat.comNeuroPace, Inc. Reports Record Revenue and Strong Margins in Q2 2025 Earnings CallAugust 31, 2025 | tipranks.comNeuroPace to Participate in Upcoming Healthcare ConferencesAugust 28, 2025 | businesswire.comNeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 21, 2025 | marketbeat.com466,015 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Acquired by Lord Abbett & CO. LLCAugust 19, 2025 | marketbeat.comQ3 Earnings Estimate for NeuroPace Issued By HC WainwrightAugust 19, 2025 | marketbeat.comQ1 Earnings Forecast for NeuroPace Issued By HC WainwrightAugust 17, 2025 | marketbeat.comCantor Fitzgerald Lifts Earnings Estimates for NeuroPaceAugust 17, 2025 | marketbeat.comFY2025 EPS Forecast for NeuroPace Increased by AnalystAugust 17, 2025 | marketbeat.comNeuroPace FY2029 EPS Estimate Boosted by Leerink PartnrsAugust 16, 2025 | marketbeat.comDeutsche Bank AG Grows Position in NeuroPace, Inc. (NASDAQ:NPCE)August 16, 2025 | marketbeat.comWells Fargo & Company Has Lowered Expectations for NeuroPace (NASDAQ:NPCE) Stock PriceAugust 15, 2025 | marketbeat.comNeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings ResultsAugust 14, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comNeuroPace Reports Record Revenue and Raises GuidanceAugust 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVR, BBNX, NPCE, and DCTH Company DescriptionsAnteris Technologies Global NASDAQ:AVR$4.02 -0.08 (-1.95%) As of 03:24 PM EasternAnteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.Beta Bionics NASDAQ:BBNX$19.88 +0.20 (+1.02%) As of 03:25 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Delcath Systems NASDAQ:DCTH$11.01 +0.11 (+1.01%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.NeuroPace NASDAQ:NPCE$9.60 +0.24 (+2.51%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Ambarella's Earnings Prove Its Edge AI Strategy Is a Winner Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
